GAPDH and neoplasm: Similarly, CD49fhiCD24low tumor cells exhibited significantly lower expression of EGR1 (−20-fold, p = 0.02), glucose transporter 3 (SLC2A3; −50-fold, p = 0.03), and GAPDH (−100-fold, p = 0.01) than benign cell counterparts.